A NEW ERA OF ANTICOAGULATION

BIBLIOGRAPHY

• Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285–295.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178–2185.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a ran-domised, double-blind, non-inferiority trial. Lancet 2007; 370: 949–956.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139–1151.
   PubMed Web of Science ®Google Scholar
• Uchino K, Hernandez AV. Dabigatran Association With Higher Risk of Acute Cor-onary Events. Meta-analysis of noninferiority Randomized Controlled Trials. Arch Intern Med 2012; 172: 397–402.
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Oldgren J, Yang S et al. Myocardial Ischemic Events in Patients with Atrial Fibrillation Treated with Dabigatran or Warfarin in the RE-LY Trial. Circulation 2012; 125: 669–676.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treat-ment of acute venous thromboembolism. N Engl J Med 2009; 361:2342–2352.
   PubMed Web of Science ®Google Scholar
• Douxfils J, Mullier F, Robert S et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for moni-toring of dabigatran etexilate. Thromb Haemost 2012; 107: 985–997.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. Summary of Products Characteristics: Pradaxa (Dabiga-tran Etexilate). European Medicines Agency 2008; 1–10.
   Google Scholar
• Kubitza D, Becka M, Voith B et al. Safety, pharmacodynamics, and pharmacoki-netics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78:412–421.
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Wensing G et al. Safety, pharmacodynamics, and pharma-cokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873–880.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Friedman RI et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765–2775.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372:31–39.
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for throm-boprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776–2786.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.
   PubMed Web of Science ®Google Scholar
• The Einstein Investigators. Oral rivaroxaban for symptomatic venous thrombo-embolism. N Engl J Med 2010; 363: 2499–2510.
   PubMed Web of Science ®Google Scholar
• The Einstein-PE Investigators. Oral rivaroxaban for the treatment of sympto-matic pulmonary embolism. N Engl J Med 2012; 366: 1287–1297.
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9–19.
   PubMed Web of Science ®Google Scholar
• Bayer. Rivaroxaban. A practical guide. Available at: http://www.thrombosis-guidelinesgroup.beisitesidefault/files/Rivaroxaban%20Practical%20Guide%20V1%200_06-07-2012.pdf
   Google Scholar
• Lassen MR, Gallus A, Raskob GE et al. Apixaban versus Enoxaparin for Throm-boprophylaxis after Hip Replacement. N Engl J Med 2010; 363: 2487-2498. (21)
   Google Scholar
• Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365: 981–992.
   PubMed Web of Science ®Google Scholar
• Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects. Circulation 2011; 124: 1573–1579.
   PubMed Web of Science ®Google Scholar
• Marlu R, Hodaj E, Paris A et al. Effect of non-specific reversal agents on anticoagu-lant activity of dabigatran and rivaroxaban. Thromb Haemost 2012; 108: 217–224.
   PubMed Web of Science ®Google Scholar